Skip to main content
Log in

The Clinical Role of Changes of Maximum Expiratory Flow at 25% and 50% of Vital Capacity before and after Bronchodilator Reversibility Test in Diagnosing Asthma

  • Published:
Current Medical Science Aims and scope Submit manuscript

Summary

Changes of maximum expiratory flow at 25% and 50% of vital capacity (MEF25 and MEF50, respectively), and predominant parameters indicating small airways function in asthmatics before and after bronchodilator (BD) reversibility test have been less interpreted. Our study aimed to investigate the clinical role of changes of MEF25 and MEF50 before and after BD reversibility test in diagnosing asthma. Forced expiratory volume in the first second (FEV1), MEF25, and MEF50 were measured before and after BD reversibility test in 207 asthmatic patients using standard process. Forty healthy individuals were enrolled as controls. Receiver operating characteristic (ROC) curve was used to assess the diagnostic accuracy of reversibility of MEF25 and MEF50 before and after BD reversibility test (ΔMEF25% and ΔMEF50%, respectively) in diagnosing asthma. Among these functional criteria, ΔMEF25% and ΔMEF50% ≥ 25% performed the best diagnostic performance. The sensitivity, specificity, and accuracy of ΔMEF25% ≥ 25% as an objective diagnostic test for asthma were 63.29%, 87.50%, and 67.21%, and of ΔMEF50% ≥ 25% were 79.23%, 85.00%, and 80.16%, respectively. The area under the ROC curve of the indicators was 0.8203 and 0.9104, respectively. By contrast, an increase in FEV1 ≥ 12% and 200 mL demonstrated a sensitivity of 62.32%, specificity of 82.50%, and accuracy of 65.59% in diagnosing asthma. The changes of MEF25 and MEF50 before and after BD reversibility test may be of additional value in the clinical diagnosis of asthma, with cutoff values of 25% being the most.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, http://ginasthma.org/; 2016 [accessed 20 March 2016].

  2. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J, 2005,26(2):319–338

    Article  CAS  Google Scholar 

  3. Tavares ECA, Matos P, Tavares B, et al. Alternative functional criteria to assess airflow-limitation reversibility in asthma. Rev Port Pneumol, 2015,21(02):69–75

    PubMed  Google Scholar 

  4. Hyatt RE, Scanlon PD, Nakamura M. Interpretation of Pulmonary Function Tests: A Practical Guide. 4th edition. Philadelphia: Wolters Kluwer Healt, 2014

    Google Scholar 

  5. Hamid Q. Pathogenesis of small airways in asthma. Respiration, 2012,84(1):4–11

    Article  CAS  Google Scholar 

  6. Finkas LK, Martin R. Role of small airways in asthma. Immunol Allergy Clin North Am, 2016,36(3):473–482

    Article  Google Scholar 

  7. Burgel, PR. The role of small airways in obstructive airway diseases. Eur Respir Rev, 2011,20(119):23–33

    Article  Google Scholar 

  8. American Thoracic Society. Guidelines for methacholine and exercise challenge testing-1999. Am J Respir Crit Care Med, 2000,161:309–329

    Article  Google Scholar 

  9. Vergnon JM, Costes F, Bayon MC, et al. Efficacy of tracheal and bronchial stent placement on respiratory functional tests. Chest, 1995,107(3):741–746

    Article  CAS  Google Scholar 

  10. Wu JZ, Ma LJ, Zhao LM, et al. Significance of fractional exhaled nitric oxide combined with serum procalcitonin and C-reactive protein in evaluation of elderly asthma. J Huazhong Univ Sci Technolog Med Sci, 2013,33(2):185–188

    Article  CAS  Google Scholar 

  11. van den Berge M, Ten Hacken NHT, Cohen J, et al. Small airway disease in asthma and COPD: Clinical implications. Chest, 2011,139(2):412–423

    Article  Google Scholar 

  12. Bonini M, Usmani OS. The role of the small airways in the pathophysiology of asthma and chronic obstructive pulmonary disease. Ther Adv Respir Dis, 2015,9(6):281–293

    Article  Google Scholar 

  13. Takishima T. Flow-volume curve and small airway diseases. Kokyu to Junkan, 1977,25(1):19–26

    CAS  PubMed  Google Scholar 

  14. Gelb AF, Macanally BJ. Early detection of obstructive lung disease by analysis of maximal expiratory flow-volume curves. Chest, 1973,64(6):749–753

    Article  CAS  Google Scholar 

  15. Guo XX, Deng NS, Chen QH, et al. Application of Inflammatory Markers in Induced Sputum in Stable Chronic Obstructive Pulmonary Disease Patients With Positive Bronchodilation Tests. Curr Med Sci, 2019,39(4):560–567

    Article  CAS  Google Scholar 

  16. Corvol H, Burchard EG. Pharmacogenetic response to albuterol among asthmatics. Pharmacogenomics, 2008,9(5):505–510

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Han-xiang Nie.

Ethics declarations

The authors declare that there is no conflict of interest with any financial organization or corporation or individual that can inappropriately influence this work.

Additional information

This project was supported by the National Natural Science Foundation of China (No. 81970024) and partly by Scientific Research Project of Wuhan Health Committee (No. WX16C45).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guo, Xx., Liu, Xf., Wang, Al. et al. The Clinical Role of Changes of Maximum Expiratory Flow at 25% and 50% of Vital Capacity before and after Bronchodilator Reversibility Test in Diagnosing Asthma. CURR MED SCI 40, 677–682 (2020). https://doi.org/10.1007/s11596-020-2237-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-020-2237-6

Key words

Navigation